ResearcherShenzhen UniversityActive in the last 2 years
Jiliang Zhao
Matched on OpenAlex author ID A5020026373. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2024: 2 papers · 2025: 1 paper
Papers 3
- Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.omton.2025.201021↗
- An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2024.149931↗
- Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer. Co-author DOI 10.1186/s12951-024-02369-9↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Youjia Cao · 2 shared papers, 2024–2025 · strength 0.41
- Paper Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic can… DOI 10.1016/j.omton.2025.201021↗
- Paper An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine p… DOI 10.1016/j.bbrc.2024.149931↗
- Feilong Zhou · 2 shared papers, 2024–2025 · strength 0.41
- Paper Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic can… DOI 10.1016/j.omton.2025.201021↗
- Paper An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine p… DOI 10.1016/j.bbrc.2024.149931↗
- Cuizhu Zhang · 2 shared papers, 2024–2025 · strength 0.41
- Paper Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic can… DOI 10.1016/j.omton.2025.201021↗
- Paper An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine p… DOI 10.1016/j.bbrc.2024.149931↗
- Hongkai Zhang · 2 shared papers, 2024 · strength 0.37
- Haoqi Zhang · 1 shared paper, 2024 · strength 0.18
- Xinglu Huang · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.